Abstract
Lung cancer is one of the most common malignancies in the United States and the most lethal. Non-small-cell lung cancer (NSCLC), which accounts for over 80% of all lung cancer cases, results in a particularly poor prognosis and a high mortality rate. The 5-year survival rate is still only 15%, and most patients ultimately die from this disease. Unfortunately, the therapeutic improvements resulting from the new generation of cytotoxic agents seems to have reached a plateau. Targeted therapeutics, or agents aimed at specific biologic pathways, represent a potential for great improvements in survival from this disease. Because of their greater specificity, targeted therapeutics have the potential for decreased toxicity and increased efficacy. The main categories of targeted therapies applicable for NSCLC include receptor-targeted therapy, signal transduction or cell-cycle inhibition, angiogenesis inhibition, gene therapy, and vaccines. These new agents are, in theory, more target-specific, less toxic, easier to administer, and may lead to enhanced safety and survival for patients with advanced NSCLC. Targeted therapies are in different phases of clinical testing and have shown encouraging activity as single agents or in combination with chemotherapy as well as radiation therapy. Herein we explore targeted therapy in combination with gemcitabine.
Original language | English (US) |
---|---|
Pages (from-to) | 217-223 |
Number of pages | 7 |
Journal | Clinical Lung Cancer |
Volume | 4 |
Issue number | 4 |
DOIs | |
State | Published - Jan 2003 |
Keywords
- Angiogenesis
- Endostatin
- Farnesyltransferase inhibitors
- Gefitinib
- Inhibitors
- Marimastat
- Protein kinase C
- Receptor-targeted therapies
- Trastuzumab
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research